Alprazolam
As of the edition of 20 October 2026, Alprazolam is a small molecule: marketed, first approved in 1981 (CA); acts on GABRA1, GABRA2 and GABRA3 and 4 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2009
- Kind
- Small molecule
- Brand name
- Xanax
- First approved
- 31 December 1981 (CA)
- Approvals on record
- 18 in 5 regions
- Holder of the most recent approval
- VIATRIS FARMACEUTICA DO BRASIL LTDA; 7 holders in all
- Registered trials
- 58, 5 stopped early
- Disease areas
- Mental health; Nervous system; Hormones; Immune system; Nutrition and metabolism; Chemically induced
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company-target row on route B because of this drug.
Companies on route B for this drug
In the product1 company-target row is on route B because of Alprazolam.
See the 1 company-target row on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
| Gene | Protein | UniProt |
|---|---|---|
| GABRA1 | Gamma-aminobutyric acid receptor subunit alpha-1 | P14867 |
| GABRG2 | Gamma-aminobutyric acid receptor subunit gamma-2 | P18507 |
| GABRA5 | Gamma-aminobutyric acid receptor subunit alpha-5 | P31644 |
| GABRA3 | Gamma-aminobutyric acid receptor subunit alpha-3 | P34903 |
| GABRA2 | Gamma-aminobutyric acid receptor subunit alpha-2 | P47869 |
| GABRG1 | Gamma-aminobutyric acid receptor subunit gamma-1 | Q8N1C3 |
| GABRG3 | Gamma-aminobutyric acid receptor subunit gamma-3 | Q99928 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 3 | 1 | 2 | 0 |
| Phase 1 | 35 | 30 | 0 | 3 |
| Phase 2 | 6 | 4 | 1 | 0 |
| Phase 3 | 1 | 0 | 0 | 1 |
| Phase 4 | 13 | 9 | 1 | 1 |
| All trials | 58 |